Short Interest in 20/20 Biolabs Inc (NASDAQ:AIDX) Decreases By 36.0%

20/20 Biolabs Inc (NASDAQ:AIDX) was the target of a significant decline in short interest during the month of June. As of June 30th, there was short interest totaling 186,863 shares, a decline of 36.0% from the June 15th total of 291,990 shares. Currently, 1.5% of the company’s stock are short sold. Based on an average daily trading volume, of 424,508 shares, the days-to-cover ratio is presently 0.4 days.

20/20 Biolabs Stock Down 2.3%

Shares of AIDX opened at $0.52 on Friday. The company has a market capitalization of $6.34 million and a P/E ratio of -1.85. The firm’s 50 day moving average price is $0.83. 20/20 Biolabs has a twelve month low of $0.51 and a twelve month high of $50.00.

20/20 Biolabs (NASDAQ:AIDX) last announced its quarterly earnings data on Wednesday, May 20th. The company reported ($0.28) earnings per share for the quarter. The company had revenue of $0.35 million for the quarter.

Wall Street Analysts Forecast Growth

Several research firms have commented on AIDX. Weiss Ratings assumed coverage on 20/20 Biolabs in a report on Thursday, May 14th. They issued a “sell (e-)” rating on the stock. Maxim Group began coverage on 20/20 Biolabs in a report on Monday, May 11th. They set a “buy” rating and a $5.00 price target for the company. One analyst has rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, 20/20 Biolabs has an average rating of “Hold” and an average target price of $5.00.

20/20 Biolabs Company Profile

We develop and commercialize AI-powered, laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases. We offer two families of lab tests, both under our OneTest brand: (i) OneTest for Cancer, a multi-cancer early detection, or MCED, blood test which has been our primary commercial focus and source of revenues since we wound down our COVID-19 testing business, and (ii) OneTest for Longevity, which measures inflammatory biomarkers, that we expect to launch in the first half of 2026.